update on compounded semaglutide With B6 (Pyridoxine) Drugmakers battle pharmacies over compounded

Statements made regarding our products have not been evaluated by the U.S

Work focuses on receptor pharmacology and pathway profiling exclusively in controlled, non-clinical in-vitro environments

Part II: Team Assembly, Process Design, and Scope Building the Right Team A patent attorney working alone on pharmaceutical M&A diligence will miss things

Self-directed schedule changes carry risks that have not been studied in controlled settings

Cautionary Note Regarding Forward-Looking Statements This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended